PMID- 26609914
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20211204
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 82
IP  - 5
DP  - 2016 Nov
TI  - Therapeutic potential of mTOR inhibitors for targeting cancer stem cells.
PG  - 1180-1188
LID - 10.1111/bcp.12844 [doi]
AB  - The mammalian target of rapamycin (mTOR) pathway is aberrantly activated in many 
      cancer types. As the intricate network of regulatory mechanisms controlling mTOR 
      activity is uncovered, more refined drugs are designed and tested in clinical 
      trials. While first generation mTOR inhibitors have failed to show clinical 
      efficacy due partly to the feedback relief of oncogenetic circuits, newly 
      developed inhibitors show greater promise as anti-cancer agents. An effective 
      drug must defeat the cancer stem cells (CSCs) while sparing the normal stem 
      cells. Due to its opposing role on normal and malignant stem cells, mTOR lends 
      itself very well as a therapeutic target. Indeed, a preferential inhibitory 
      effect on CSCs has already been shown for some mTOR inhibitors. These results 
      provide a compelling rationale for the clinical development of mTOR-targeted 
      therapies.
CI  - (c) 2015 The British Pharmacological Society.
FAU - Francipane, Maria Giovanna
AU  - Francipane MG
AD  - McGowan Institute for Regenerative Medicine, Department of Pathology, University 
      of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA. francipa@pitt.edu.
AD  - Ri.MED Foundation, 90133, Palermo, Italy. francipa@pitt.edu.
FAU - Lagasse, Eric
AU  - Lagasse E
AD  - McGowan Institute for Regenerative Medicine, Department of Pathology, University 
      of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151226
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Neoplastic Stem Cells/*drug effects
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
PMC - PMC5061787
OTO - NOTNLM
OT  - cancer stem cells, drug resistance
OT  - mTOR
OT  - personalized medicine
OT  - tumour heterogeneity
EDAT- 2015/11/27 06:00
MHDA- 2017/12/30 06:00
PMCR- 2017/11/01
CRDT- 2015/11/27 06:00
PHST- 2015/09/17 00:00 [received]
PHST- 2015/11/20 00:00 [revised]
PHST- 2015/11/23 00:00 [accepted]
PHST- 2015/11/27 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
PHST- 2015/11/27 06:00 [entrez]
PHST- 2017/11/01 00:00 [pmc-release]
AID - BCP12844 [pii]
AID - 10.1111/bcp.12844 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2016 Nov;82(5):1180-1188. doi: 10.1111/bcp.12844. Epub 2015 
      Dec 26.